2seventy bio’s Board Elections and Financial Oversight Update
PremiumCompany Announcements2seventy bio’s Board Elections and Financial Oversight Update
3M ago
2seventy Bio downgraded to Sell from Neutral at Goldman Sachs
Premium
The Fly
2seventy Bio downgraded to Sell from Neutral at Goldman Sachs
4M ago
2seventy Bio price target lowered to $11 from $12 at Canaccord
Premium
The Fly
2seventy Bio price target lowered to $11 from $12 at Canaccord
4M ago
Bristol Myers, 2seventy Bio’s Abecma approved by U.S. FDA
PremiumThe FlyBristol Myers, 2seventy Bio’s Abecma approved by U.S. FDA
6M ago
Fly Insider: 2seventy bio, Coinbase among week’s notable insider trades
Premium
The Fly
Fly Insider: 2seventy bio, Coinbase among week’s notable insider trades
6M ago
2seventy bio Finalizes Asset Sale and Executive Transition
Premium
Company Announcements
2seventy bio Finalizes Asset Sale and Executive Transition
6M ago
2seventy bio trading halted, news pending
PremiumThe Fly2seventy bio trading halted, news pending
6M ago
2seventy Bio price target lowered to $12 from $20 at Canaccord
Premium
The Fly
2seventy Bio price target lowered to $12 from $20 at Canaccord
7M ago
2seventy Bio: Abecma generated $56M U.S. commercial revenue in Q4
Premium
The Fly
2seventy Bio: Abecma generated $56M U.S. commercial revenue in Q4
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100